ARTICLE | Company News

Broda Tech, Redwood Pharma deal

August 3, 2015 7:00 AM UTC

Broda granted Redwood exclusive, worldwide rights to use IntelliGel supramolecular hydrogel technology for ophthalmic indications. Redwood has reformulated its RP101 -- a daily topical eye treatment based on a naturally occurring endogenous molecule -- using IntelliGel for use in postmenopausal women to treat chronic dry eye syndrome. The company is planning a Phase II trial of the product. Broda is eligible for milestones and royalties. ...